Sentences with phrase «used tumour cells»

Using tumour cells in the lab, as well as mini lab - grown tumours called organoids, Coleman hopes to reveal more about the role these faulty molecules — called protein «hydroxylases» — have in cancer.

Not exact matches

They then plan to use a retrovirus to introduce the artificial gene into tumour cells.

A «Trojan horse» treatment for an aggressive form of brain cancer, which involves using tiny nanoparticles of gold to kill tumour cells, has been successfully tested by scientists.

A DEVICE that filters cancer cells from human blood using sound could help to identify tumour cells that have spread.

We are looking for the proteins that make the tumour cells different to the host devils that they infect and then use these «tumour specific» proteins to design a vaccine that will save the devil from extinction.

Now, the researchers have discovered an alternative in a mouse model: in the case of breast tumours with a specific defect in DNA repair, the animals can be cured using already established, cheap chemotherapy drugs, if enough DNA damage can be inflicted on the resting tumour cells.

This would then use the protein to recognise a foreign or tumour cell, attach to it and release the toxin in a high local concentration, which would cause the death of the tumour cell.

The test can be used for diagnosis of malignant germ cell tumours in any part of the body, including the brain.

Using an approach developed at Maisonneuve - Rosemont, consisting of an autograft to reduce tumour mass followed by a family allograft three to four months later to clean the bone marrow of myeloma cells with immune cells from a family donor (immunotherapy), the study resulted in a total cure rate of 41 %, a record level using this straUsing an approach developed at Maisonneuve - Rosemont, consisting of an autograft to reduce tumour mass followed by a family allograft three to four months later to clean the bone marrow of myeloma cells with immune cells from a family donor (immunotherapy), the study resulted in a total cure rate of 41 %, a record level using this strausing this strategy.

Growing mini tumours in the lab from a patient's own cells could help doctors discover the best way to treat each person, homing in on the right drugs to use

Saurabh Saha of BioMed Valley Discoveries in Kansas City, Missouri, and his colleagues wondered whether they could use the bacteria to selectively kill mammalian cells within cancerous tumours, which often have a poor blood supply and therefore low oxygen levels.

The team used five types of antibiotics — including one used to treat acne (doxycycline)-- on cell lines of eight different types of tumour and found that four of them eradicated the cancer stem cells in every test.

The new device will allow for more accurate medical procedures that involve the use of ultrasound to kill tumours, loosen blood clots and deliver drugs into targeted cells.

So if biologists can discover how to disable cancer cells» DNA repair proteins, it may be possible to destroy tumours using lower doses of radiation or drugs.

If these could be targeted to tumours — by attaching them to antibodies that recognise cancer cells, for instance — it would then be possible to destroy the malignant cells» DNA using lower doses of radiation or drugs.

But at the moment we have to use retroviruses to carry the foreign material into the cells, which could generate tumours.

This involves crushing live tumour cells and measuring the metabolites they contain using a mass spectrometer.

To analyse the tumour cells» metabolism, they used a technique called «metabolomics ``.

To do this, they switched from using dead tumour cell samples to patient - derived tumour cell lines, in which fresh samples of a person's tumour are grafted onto mice and grown to the required volumes.

In lab experiments, the research team used cell lines derived from 40 patient tumour samples to identify that CD151 contributes to the survival of cells of high - grade serous ovarian cancer origin.

The existence of cancer stem cells has already been reported in a number of human cancers, explains Professor Jacobsen, but previous findings have remained controversial since the lab tests used to establish the identity of cancer stem cells have been shown to be unreliable and, in any case, do not reflect the «real situation» in an intact tumour in a patient.

Using genetic tools to establish in which cells cancer - driving mutations originated and then propagated into other cancer cells, they demonstrated that a distinct and rare subset of MDS cells showed all the hallmarks of cancer stem cells, and that no other malignant MDS cells were able to propagate the tumour.

A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

Using a CRISPR - dCas9 epigenetic editing tool, the researchers methylated different genes in healthy breast cells and found that those changes were sufficient to cause the cells to undergo «hyperproliferation» — abnormally rapid cell division which is an early stage of tumour initiation.

After injecting them into the bloodstream, we are able to gather them around the tumour using magnets and ensure that they don't kill the healthy cells,» explains Asst Prof Xu, who has been working on cancer diagnosis and drug delivery systems since 2004.

In spite of the difference between the cell functions responsible for giving rise to a tumour and for the metastasis of this same tumour, studies at IRB Barcelona using the fly Drosophila melanogaster reveal that some genes can drive both phenomena.

Geneva, Switzerland, 26 March 2014 — A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

An alternative approach is to persuade the immune system to attack tumours, using vaccines, biological therapies such as alpha interferon or interleukin 2 and genetically altered white blood cells.

«It suggests to us that targeting the pathways used in regulating cell fate decisions — how stem cells choose between cell proliferation and differentiation — could be a more effective way of halting tumours in their tracks and lead to potential new therapies.»

We have identified a number of key transcription factors that are deregulated during this process, and we are using this information to investigate mechanisms by which differentiation can be reprogrammed in tumour cells.

Another approach, still early in clinical development, uses antibodies to vaccinate patients against their own tumours, pushing their immune system to attack the cancer cells.

Her group has developed pre-clinical models of metastatic disease that are used to identify genes, both in the tumour cells and in the tumour micro-environment that regulate the process of metastasis to specific organs such as bone, liver, lung and brain.

«It tells you about the ecosystem of the tumour», Simona says, «using fluorescent markers, we can label many specific cell types and structures within the brain in the vicinity of the tumour, and look not just at the tumour cells but how they interact with their surroundings.

«We showed that there are markers on these stomach tumour cells that indicate they would be responsive to a type of immunotherapy called immune checkpoint inhibitors, in particular anti-PDL1 immunotherapy, which is already used with great success in the treatment of melanoma and certain other cancers.

In this study the researchers achieved reprogramming of adult cells without the use of a gene which has been linked to the development of tumours.

Kelley, lead investigator on the study published today in Nature Chemistry, explained how her team has advanced a completely new approach using magnetic nanoparticles with DNA capture probes on their surface that can target circulating tumour cells (CTCs) in blood samples to see if the cells contains biomarkers associated with drug resistance.

Functional imaging using in vivo confocal microscopy which allows the analysis of vaso - activity phenomena during hypoxia, of ischaemia reperfusion events, or of homing cells in pathologic processes, such as tumours or inflammatory diseases.

Areas of focus include: understanding how tumour - reactive T cells and B cells promote patient survival in cancer; defining the effects of standard treatments on tumor immunity; and using genomic approaches to identify novel tumour mutations that can serve as target antigens for immunotherapy.

Within the scope of personalized medicine, this technology presents immense possibilities for testing patient - derived multicellular tumour spheroids / organoids (comprising cancer cells, stromal cells, cancer stem cells and / or immune cells) for disease / biomarker - oriented drug activity and profiling using single - and pair-wise standard / targeted drug combinations.

Chaired by Prof. Dirk Schadendorf, talks covered topics which included: melanoma epidemiology in the in period since the start of the German National Skin Cancer screening programme (Dr Andreas Strang); an overview of melanoma therapies used in stage IV melanoma; adjuvant therapies and prognosis in stage III melanoma (Dr Lisa Zimmer); tumour heterogeneity, plasticity and resistance in melanoma (Alexander Roesch); epigenomics of normal and abnormal cell differentiation (Bernard Horsthermeke); and, genetics and epigenetics of uveal melanoma (Michael Zeschnigk).

Chemotherapy uses systemic medications that kill all fast - growing cells in the dog's body, including cells in dog tumours.